The University of Chicago Header Logo

Connection

Hans Schreiber to Female

This is a "connection" page, showing publications Hans Schreiber has written about Female.
Connection Strength

0.239
  1. CD4+ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy. Sci Immunol. 2024 09 13; 9(99):eadp6529.
    View in: PubMed
    Score: 0.041
  2. Fibroblasts: Dangerous travel companions. J Exp Med. 2019 03 04; 216(3):479-481.
    View in: PubMed
    Score: 0.028
  3. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res. 2014 Jan 15; 74(2):632; discussion 635.
    View in: PubMed
    Score: 0.020
  4. Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases. Oncoimmunology. 2025 Dec; 14(1):2514041.
    View in: PubMed
    Score: 0.011
  5. Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004 May 13; 23(22):3972-9.
    View in: PubMed
    Score: 0.010
  6. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. J Immunother Cancer. 2023 05; 11(5).
    View in: PubMed
    Score: 0.009
  7. Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. 2020 11 13; 41(11):1605-1615.
    View in: PubMed
    Score: 0.008
  8. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor ß Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. Hum Gene Ther. 2020 08; 31(15-16):863-880.
    View in: PubMed
    Score: 0.008
  9. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med. 2000 Jun 05; 191(11):1945-56.
    View in: PubMed
    Score: 0.008
  10. Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.
    View in: PubMed
    Score: 0.007
  11. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018 11; 53(11):1379-1389.
    View in: PubMed
    Score: 0.007
  12. Tumour ischaemia by interferon-? resembles physiological blood vessel regression. Nature. 2017 05 04; 545(7652):98-102.
    View in: PubMed
    Score: 0.006
  13. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med. 1997 Feb 17; 185(4):695-705.
    View in: PubMed
    Score: 0.006
  14. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens. 1996 May; 47(5):399-407.
    View in: PubMed
    Score: 0.006
  15. A unique tumor antigen produced by a single amino acid substitution. Immunity. 1995 Jan; 2(1):45-59.
    View in: PubMed
    Score: 0.005
  16. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur J Immunol. 1993 Nov; 23(11):2770-6.
    View in: PubMed
    Score: 0.005
  17. Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clin Immunol Immunopathol. 1993 Nov; 69(2):215-22.
    View in: PubMed
    Score: 0.005
  18. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med. 1993 Sep 01; 178(3):933-40.
    View in: PubMed
    Score: 0.005
  19. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2013 Aug; 1(2):123-33.
    View in: PubMed
    Score: 0.005
  20. CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation. 1993 Jun; 55(6):1349-55.
    View in: PubMed
    Score: 0.005
  21. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med. 1992 Jan 01; 175(1):139-46.
    View in: PubMed
    Score: 0.004
  22. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res. 1990 Jul 01; 50(13):3851-8.
    View in: PubMed
    Score: 0.004
  23. Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity. Cell Immunol. 1989 Mar; 119(1):101-13.
    View in: PubMed
    Score: 0.004
  24. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
    View in: PubMed
    Score: 0.003
  25. CD40 ligation restores cytolytic T lymphocyte response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells. Cancer Immunol Immunother. 2006 Dec; 55(12):1542-52.
    View in: PubMed
    Score: 0.003
  26. A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity. Cancer Lett. 2005 Jun 16; 224(1):153-66.
    View in: PubMed
    Score: 0.003
  27. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004 Feb; 5(2):141-9.
    View in: PubMed
    Score: 0.002
  28. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med. 2003 Apr 21; 197(8):985-95.
    View in: PubMed
    Score: 0.002
  29. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 2002 Oct 15; 62(20):5792-9.
    View in: PubMed
    Score: 0.002
  30. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J Immunol. 2001 Jun 15; 166(12):7151-7.
    View in: PubMed
    Score: 0.002
  31. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol. 1999 Oct; 15(4):769-73.
    View in: PubMed
    Score: 0.002
  32. [Immunocytologic detection of disseminated tumor cells in the peritoneal cavity and bone marrow in patients with pancreatic carcinoma]. Chirurg. 1994 Dec; 65(12):1111-5.
    View in: PubMed
    Score: 0.001
  33. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol. 1994 Apr; 12(4):725-9.
    View in: PubMed
    Score: 0.001
  34. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A. 1990 Feb; 87(4):1486-90.
    View in: PubMed
    Score: 0.001
  35. [Clinical aspects and therapy of Merkel cell tumor--report of 4 personal cases and review of the literature]. Langenbecks Arch Chir. 1988; 373(3):173-81.
    View in: PubMed
    Score: 0.001
  36. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon]. Dtsch Med Wochenschr. 1984 Dec 21; 109(51-52):1949-54.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.